Open AccessClinical utility of chromogranin a and octreotide in large cell neuro endocrine carcinoma of the uterine corpus
Author(s) -
Shohreh Shahabi,
Ilenia Pellicciotta,
June Y. Hou,
Sarah Graceffa,
Gloria S. Huang,
Robert Samuelson,
Gary L. Goldberg
Publication year - 2011
Publication title -
rare tumors
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.285
H-Index - 15
eISSN - 2036-3613
pISSN - 2036-3605
DOI - 10.4081/rt.2011.e41
Subject(s) - medicine , radiation therapy , chromogranin a , neuroendocrine tumors , endocrine system , cervix , female circumcision , chemotherapy , uterus , octreotide , gastrointestinal tract , neuroendocrine carcinoma , pathology , carcinoma , oncology , gynecology , hormone , cancer , immunohistochemistry , somatostatin
Primary neuroendocrine tumors of the female genital tract have been described in the cervix, ovaries and uterus. Large cell neuroendocrine carcinoma (LCNC) of the uterine corpus is the least common and appears to behave the most aggressively. We report a rare case of a large cell neuroendocrine tumor of the endometrium. These tumors are not well characterized, unlike neuroendocrine tumors of the uterine cervix, consequently, the optimal management remains still unclear. The treatment of our case consisted of surgery, radiotherapy, chemotherapy, and octreotide. Despite the aggressive treatment, the patient died of disease progression 12 months after the initial diagnosis. We discuss the diagnosis, prognosis, and treatment options for LCNC of the genital tract, and potential future therapeutics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom